ZBH Stock Price Today (November 2026) — Zimmer Biomet Holdings, Inc. Analysis & Key Metrics 2026-11-06
Zimmer Biomet Holdings, Inc. (ZBH) is trading at $105.59, down 1.18% today (as of November 2026).The stock is trading above its 50-day and 200-day moving averages.
- According to consensus analyst estimates, the 1-year price target is $106.90 (1.2% upside).
- Volatility is high (56.28% annualized), above 40%.
- From the latest financial filings: Revenue grew 4.80% in the latest quarter compared with the same quarter a year earlier. Debt is 0.60 times shareholders' equity.
ZBH Stock Analysis: Key Metrics & Valuation (November 2026)
Key figures from the latest data
Zimmer Biomet Holdings, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $27.28B
P/E Ratio
Forward P/E: 10.77
Revenue Growth
Latest quarter vs year ago
Analyst Target
+1.2% upside potential
Key Investor Questions About ZBH
What the latest data shows
ZBH is trading above its 50-day and 200-day moving averages, and its RSI of 64.3 is in the neutral zone (between 30 and 70).
- Technicals: Neutral (RSI 64.26) (Uptrend: above 50- and 200-day averages)
- Fundamentals: Revenue +4.8%, debt/equity 0.60x
Revenue grew 4.80% in the latest quarter compared with the same quarter a year earlier.
- Total debt is $7.60B (0.60 times equity).
- 30-day volatility is 56.28% annualized, which counts as high (above 40%).
52-Week Trading Range
Over the past year, ZBH stock traded between $78.70 and $112.55 and currently trades in the middle of that range.
Volatility & Risk Profile
30-day volatility is 56.28% annualized, which counts as high (above 40%). Beta 0.41: the stock has moved much less than the market.
Institutional & Insider Ownership
Short interest is 5.51% of the float.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
Rothschild & Co Redburn Adjusts Price Target on Zimmer Biomet to $123 From $117
Truist Adjusts Price Target on Zimmer Biomet to $114 From $106, Maintains Hold Rating
Zimmer Biomet Sees Stronger Growth Ahead in 2027 Despite Knee Weakness, RBC Says
Baird Adjusts Price Target on Zimmer Biomet to $114 From $104
Canaccord Genuity Adjusts Price Target on Zimmer Biomet to $111 From $100
Latest TickZen Insights
All insights →No TickZen article on ZBH yet. Our newest analysis:
Explore More Analysis for ZBH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
No upcoming report date yet
Frequently Asked Questions
Common investor questions about Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH) is currently trading at $105.59. The RSI (14-day) is 64.3, in the neutral zone (between 30 and 70). Wall Street analysts have a consensus "Buy" recommendation. The mean analyst price target of $106.90 implies 1.2% upside from current levels. 30-day volatility is 56.28% annualized, which counts as high (above 40%).
Based on current valuation metrics for Zimmer Biomet Holdings, Inc. (ZBH): The trailing P/E ratio is 25.63. The forward P/E is 10.77, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 1.59. Price-to-Sales is 2.37. Different industries trade at different multiples, so these figures are most useful next to Medical Devices peers.
Based on 21 analysts covering ZBH, the consensus price target is $106.90. This represents a 1.2% upside from the current price of $105.59. The range spans from a low target of $93.00 to a high target of $130.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Zimmer Biomet Holdings, Inc. (ZBH) pays a dividend with a current yield of approximately 0.91%. The annualized dividend rate is $0.96 per share. The payout ratio is 23.3%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Sep 30, 2026.
Key risks for Zimmer Biomet Holdings, Inc. (ZBH) shown in the latest data: 1. High volatility (56.3% annualized, above 40%). 2. Moves in the broader stock market (Beta 0.41: the stock has moved much less than the market).
Here is Zimmer Biomet Holdings, Inc.'s (ZBH) current debt and financial health profile: Total debt stands at $7.60B. The debt-to-equity ratio is 0.60x, which is moderate and generally manageable for most companies. The current ratio is 1.69, indicating strong short-term liquidity. The quick ratio is 0.74. The company holds $464.50M in cash and equivalents. Free cash flow is positive at $1.51B, providing a cushion for debt servicing and shareholder returns.